The aim of this study was to evaluate the prognostic value of germline polymorphisms in key genes of the VEGF signaling pathway (VEGFA, FLT1 and KDR) in a prospective multicenter cohort of patients with localized high-grade osteosarcoma treated with the GEIS-33 protocol. This evidence concerns the gene KDR and osteosarcoma.